TNF-α inhibitors, IL-12/23 inhibitors and IL-23 inhibitors have shown efficacy, whereas JAK inhibitors may also be a promising treatment option in selected patients.4,5 However, when choosing the appropriate treatment for this condition, physicians should follow a treat-to-target strategy by simultaneously taking into consideration other manifestations of the pre-existing axSpA (uveitis, hidradenitis, etc).17 The gene discussed is TNF; the disease is uveitis.